iBio, Inc.: Business Overview, Financials & Competitive Analysis
iBio, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Pre-clinical biotech with differentiated obesity therapy pipeline entering clinical stage, well-funded through 2028, but remains high-risk until clinical proof-of-concept. iBio reported FY2025 revenue of $400,000 with improving unit economics (losses decreased 26.22% to -$18.38M). The company maintains strong preclinical progress with lead assets advancing rapidly while facing typical biotech risks.
What is iBio, Inc.'s industry? iBio, Inc. (ibioinc.com) operates in Biopharmaceutical / Precision Medicine - Obesity and Cardiometabolic Therapeutics. AskCyborg classifies iBio, Inc. under Biopharmaceutical / Precision Medicine - Obesity and Cardiometabolic Therapeutics in its company registry.
iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, com...
Cyborg Score thesis
Pre-clinical biotech with differentiated obesity therapy pipeline entering clinical stage, well-funded through 2028, but remains...
Read the full analyst-debate transcript →Get the Latest iBio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeiBio, Inc. Overview
Pro stress-test →iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases, combining proprietary 3D modeling with innovative drug discovery platforms to create breakthrough antibody treatments. The company has $52.7M in cash as of December 2025 with runway extended into Q3 FY2028.
Strategic Profile
Pro stress-test →iBio has two lead programs: IBIO-610, its activin E antibody, and IBIO-600, its myostatin antibody, both advancing toward human clinical trials with IBIO-610 on track for early 2027 and IBIO-600 planned for H1 2026. IBIO-610 has demonstrated a predicted human half-life of up to 100 days supporting potential dosing as infrequently as twice per year, positioning it as a first-in-class obesity therapeutic with distinct advantages over current GLP-1 treatments.
Competitive Landscape
Pro stress-test →iBio competes in the obesity and cardiometabolic therapeutics space against established GLP-1 agonists and emerging antibody platforms. Key differentiation lies in long-acting antibody format (twice-yearly dosing vs. weekly injections) and fat-selective weight loss mechanism. Main competitors include Novo Nordisk (Ozempic/Wegovy), Eli Lilly (Mounjaro), and emerging obesity biotech startups. iBio's AI-driven platform and 3D modeling approach provide platform durability.
Industry Context
iBio, Inc. operates in Biopharmaceutical / Precision Medicine - Obesity and Cardiometabolic Therapeutics.
Key facts
Founded: 2008 · Headquarters: San Diego, US · Employees: 20 · Revenue: $400K